Darifenacin Hydrobromide has 23 known drug interactions based on U.S. FDA drug labeling data. Notable interactions include combinations with Acidifying Agents, Clarithromycin, Erythromycin. Patients taking Darifenacin Hydrobromide should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 23
- Moderate
- 12
- Minor
- 11
Moderate (12)
- Darifenacin Hydrobromide + Acidifying Agents— Concomitant use increases frequency and severity of anticholinergic effects including dry mouth, constipation, and blurr…
- Darifenacin Hydrobromide + Clarithromycin— Potent CYP3A4 inhibitor; darifenacin daily dose should not exceed 7.5 mg when co-administered.
- Darifenacin Hydrobromide + Erythromycin— No dosing adjustments are recommended in the presence of moderate CYP3A4 inhibitors (for example, erythromycin, fluconaz…
- Darifenacin Hydrobromide + Flecainide— Caution when used concomitantly; darifenacin may increase exposure of flecainide, a CYP2D6 substrate with narrow therape…
- Darifenacin Hydrobromide + Fluconazole— No dosing adjustments are recommended in the presence of moderate CYP3A4 inhibitors (for example, erythromycin, fluconaz…
- Darifenacin Hydrobromide + Itraconazole— Potent CYP3A4 inhibitor; darifenacin daily dose should not exceed 7.5 mg when co-administered.
- Darifenacin Hydrobromide + Ketoconazole— Potent CYP3A4 inhibitor; darifenacin daily dose should not exceed 7.5 mg when co-administered.
- Darifenacin Hydrobromide + Nefazodone— Potent CYP3A4 inhibitor; darifenacin daily dose should not exceed 7.5 mg when co-administered.
- Darifenacin Hydrobromide + Nelfinavir— Potent CYP3A4 inhibitor; darifenacin daily dose should not exceed 7.5 mg when co-administered.
- Darifenacin Hydrobromide + Other Anticholinergic Agents— Concomitant use may increase frequency and/or severity of dry mouth, constipation, blurred vision and other anticholiner…
- Darifenacin Hydrobromide + Ritonavir— Potent CYP3A4 inhibitor; darifenacin daily dose should not exceed 7.5 mg when co-administered.
- Darifenacin Hydrobromide + Thioridazine— Caution when used concomitantly; darifenacin may increase exposure of thioridazine, a CYP2D6 substrate with narrow thera…
Minor (11)
- Darifenacin Hydrobromide + Digoxin— Darifenacin did not have clinically relevant effect on digoxin pharmacokinetics. Routine monitoring should continue.
- Darifenacin Hydrobromide + Diltiazem— Moderate CYP3A4 inhibitor; no dosing adjustments recommended.
- Darifenacin Hydrobromide + Duloxetine— CYP2D6 inhibitor; no dosing adjustments recommended.
- Darifenacin Hydrobromide + Ethinyl Estradiol— Component of combination oral contraceptives. Darifenacin had no effect on pharmacokinetics when combined.
- Darifenacin Hydrobromide + Fluoxetine— CYP2D6 inhibitor; no dosing adjustments recommended.
- Darifenacin Hydrobromide + Levonorgestrel— Component of combination oral contraceptives. Darifenacin had no effect on pharmacokinetics when combined.
- Darifenacin Hydrobromide + Midazolam— CYP3A4 substrate. Darifenacin did not have significant impact on midazolam pharmacokinetics.
- Darifenacin Hydrobromide + Paroxetine— CYP2D6 inhibitor; no dosing adjustments recommended.
- Darifenacin Hydrobromide + Quinidine— CYP2D6 inhibitor; no dosing adjustments recommended.
- Darifenacin Hydrobromide + Verapamil— Moderate CYP3A4 inhibitor; no dosing adjustments recommended.
- Darifenacin Hydrobromide + Warfarin— Darifenacin had no significant effect on prothrombin time. Standard monitoring should continue.